ライブ

FierceBiotechIn another reversal for rare disease field, FDA to reconsider Regenxbio gene therapy Endpoints NewsMerck's IBD drug from $10.8B Prometheus deal claims its first Phase 3 win FierceBiotechMerck’s anti-TL1A antibody from Prometheus buyout passes ph. 3 test in ulcerative colitis PharmaVoicePfizer CFO departs for consumer goods sector FierceBiotechSanofi, Pangaea ink AI partnership deal to detect underdiagnosed genetic disease PharmaVoiceBacked by Sanofi and Roche, Orano Med chases radiopharma leadership BioWorldBrightgene Bio-Medical Technology synthesizes new GIPR, GCGR and GLP-1R agonists BioWorldTennor Therapeutics discovers new antibacterial agents BioWorldAsahi Kasei Therapeutics reports new TNFR1 antagonists BioWorldNLRP3 inflammasome inhibitors disclosed in Evotec patent BioWorldF2G preps NDA for first new antifungal in 20 years on solid phase III Labiotech8 of the most expensive drugs in biopharma: Unraveling the costliest medications

FierceBiotech 2026年6月22日

Helmed by Sanofi vet, Bionyara emerges with $165M and three licensed I&I assets

Bionyra is emerging from stealth with an oversubscribed Series A round of $165 million co-led by Jeito Capital and Sofinnova Partners. Arkin Bio, Sanofi Venture...

Bionyra is emerging from stealth with an oversubscribed Series A round of $165 million co-led by Jeito Capital and Sofinnova Partners. Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners and Apollo Health Ventures also participated in the round after the company received seed financing from Sofinnova Partners.